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Abstract 
Metastatic disease is the principle cause of death from colorectal cancer. In that context, the most 
significant indicator of overall survival and therapeutic response to adjuvant chemotherapy is the 
presence of metastatic tumor cells in regional lymph nodes. Although histopathologic analysis of 
lymph nodes is central to all colorectal cancer staging paradigms, its prognostic and predictive 
value is limited. Indeed, about 30% of patients with histopathology-negative lymph nodes (pN0) die 
from metastatic disease, reflected by microscopic lymph node metastases that are overlooked by 
standard techniques. These unrecognized tumor cells are especially important when considering 
racial disparities in outcomes in colorectal cancer patients, where blacks with lymph node-negative 
disease have the largest discrepancies in outcomes, with more than 40% excess mortality com-
pared to Caucasian patients. However, the significance of tumor cells in regional lymph nodes 
remains uncertain, and approximately 50% of colorectal cancer patients with nodal metastases 
detected by histopathology remain free of recurrent disease. Accurate identification of occult 
metastases in regional lymph nodes, and defining their value as prognostic markers of recurrence 
risk and predictive markers of response to adjuvant chemotherapy remains one challenge in the 
management of colorectal cancer patients. Guanylyl cyclase C (GUCY2C), a receptor which is 
expressed primarily in intestinal cells normally, but is universally over-expressed by colorectal 
cancer cells, has been validated to detect prognostically significant occult metastases using quan-
titative RT-PCR (RT-qPCR). Biomarker validation was achieved through a prospective, multi-
center, blinded clinical trial. In that trial, occult tumor burden estimated across all regional lymph 
nodes by GUCY2C RT-qPCR predicted clinical outcomes, identifying node-negative patients with 
a low (near zero) risk, and those with >80% risk, of developing disease recurrence. Moreover, 
there was disproportionately higher occult tumor burden in black, compared to white, patients 
which contributes to racial disparities in outcomes in colorectal cancer. The diagnostic paradigm 
quantifying occult tumor burden using GUCY2C qRT-PCR is positioned to reduce racial dispari-
ties in colorectal cancer mortality. 
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Introduction 
Metastases continue to be the principle cause of 
mortality from colorectal cancer. In colorectal cancer 
staging patients, the most significant prognostic in-
dicator of survival and predictive indicator of re-
sponse to adjuvant therapy are metastatic cancer cells 
in regional lymph nodes [1-3]. While histopathologic 
assessment of lymph nodes is a core element of colo-
rectal cancer staging algorithms, the prognostic and 
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predictive value of lymph node metastases is re-
stricted [1-5]. Thus, about 30% of patients with histo-
pathology-negative regional lymph nodes (stage I and 
II) develop recurrent disease, likely reflecting the 
presence of undetected metastases in those lymph 
nodes [1-3]. Moreover, these undetected metastases 
take on particular significance when considering ra-
cial disparities in colorectal cancer outcomes: African 
Americans with node-negative colorectal cancer are 
disadvantaged, with more than 40% excess mortality 
compared to Caucasian patients with the same disease 
[6-9]. However, the absolute significance of metastatic 
tumor cells in lymph nodes remains unclear, and ap-
proximately 50% of patients with lymph node metas-
tases identified by histopathology (stage III) remain 
free of disease recurrence [1-3]. This discussion high-
lights the central importance of understanding how to 
identify regional lymph node metastases and evaluate 
their prognostic and predictive significance in man-
aging black and white patients with colorectal cancer 
[1-5, 10]. 
Guanylyl cyclase C (GUCY2C) is a receptor 
which is typically restricted to intestinal epithelial 
cells normally, but is universally over-expressed by 
colorectal cancer cells. Because of this unique expres-
sion pattern, GUCY2C was validated to detect prog-
nostically significant occult colorectal metastases by 
quantitative RT-PCR (RT-qPCR). Validation was 
achieved through a prospective, multicenter, blinded 
clinical trial [11]. This biomarker platform has been 
employed to generate a molecular staging algorithm 
that quantifies occult metastatic cancer burden across 
the regional lymph node network. In turn, this ap-
proach identifies histopathology node-negative colo-
rectal cancer patients with near-zero risk, and those 
with >80% risk, of developing disease recurrence 
[12-14]. Moreover, there is disproportionate occult 
tumor burden in African American, compared to 
Caucasian, colorectal cancer patients which contrib-
utes to racial disparities in outcomes in this disease 
[12]. 
Colorectal Cancer 
Colorectal cancer continues to be the fourth most 
common cause of cancer, with about 140,000 new 
cases annually, and the second leading cause of cancer 
mortality, resulting in approximately 10% of can-
cer-related deaths, or ~50,000 patients annually, in the 
U.S. [1, 3, 15]. The significant impact of this disease 
can best be appreciated by considering the communi-
ties at risk, which in the U.S. include >100 million 
people >50 years. In colorectal cancer, mortality re-
flects metastatic disease, and about 20% of patients 
have unresectable disease at presentation while more 
than 30% develop metastases after diagnosis. Surgery 
continues to be the mainstay of management [1-3]. 
Yet, while “curative” surgery removes obvious tumor, 
occult metastatic disease produces recurrences [1-3]. 
Indeed, recurrence rates range from about 10% for 
disease limited to the epithelium (stage I) to more 
than 60% for cancer that has metastasized to more 
than 4 regional lymph nodes (stage III) [1-3]. 
Staging 
The most significant prognostic marker of risk of 
disease recurrence in colorectal cancer is metastatic 
tumor cells in regional lymph nodes [1-3]. However, 
current approaches to detecting metastases in regional 
nodes remain inaccurate and their clinical significance 
is not certain. While histopathology is the standard 
approach, imprecision in staging by standard light 
microscopy signifies significant methodological limi-
tations [1-5, 11]. Thus, this approach is insensitive, 
with the limit for detection of ~1 cancer cell in 200 
normal cells in lymph nodes [16]. Further, typically 
only one or a few sections from each lymph node are 
examined, leaving more than 99.99% of each specimen 
not reviewed, producing sampling error. Such limita-
tions are evident when post-resection disease recur-
rence frequency is considered. Stage I and II disease, 
limited to the intestinal wall without obvious evi-
dence of spread beyond the bowel, should be curable 
by surgery. Yet, rates of recurrence can be as high as 
15% in stage I and 30% in stage II disease [1-3, 17]. 
Conversely, while all stage III patients have metasta-
ses in regional lymph nodes, only about 50% develop 
recurrent metastatic disease. Thus, about 50% of col-
orectal patients with nodal metastases visible by mi-
croscopy remain disease-free. In that context, molec-
ular markers that certify the clinical significance of 
metastases in regional lymph nodes have yet to be 
identified. Indeed, identifying regional lymph node 
metastases and their clinical importance represents an 
important gap in managing colorectal cancer patients 
[10]. 
Beyond predicting disease recurrence, metasta-
ses in regional lymph nodes identify patients who 
benefit from adjuvant chemotherapy. Adjuvant 
chemotherapy incorporating 5-fluorouracil (5-FU) 
and irinotecan or oxaliplatin, increases 5 year survival 
from ~40% (untreated) to ~50% (treated) in patients 
with stage III colon cancer [2, 18]. Limited therapeutic 
benefit in some, but not all, patients with stage III 
disease probably reflects stage heterogeneity, in 
which some patients have clinically aggressive me-
tastases. One limitation to managing these patients is 
the inability to recognize clinically significant regional 
lymph node metastases, resulting in toxic therapies 
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being administered to patients who derive no benefit, 
and may suffer adverse reactions. This scenario is 
even more complex for patients with stage I and II 
disease who are lymph node-negative by histo-
pathology. Indeed, here, the utility of therapy is un-
certain, with small survival benefits revealed for stage 
II patients in only some clinical trials [18, 19]. This 
discussion highlights the unmet need for approaches 
that detect occult tumor cells and define their prog-
nostic and predictive value, to identify colorectal 
cancer patients who derive the greatest benefit from 
therapy [10]. 
Racial disparities 
While mortality from colorectal cancer decreas-
es, there is an increasing racial gap in incidence and 
outcomes [9, 20, 21]. There is about a 20% greater in-
cidence of, and approximately a 40% greater death 
rate from, colorectal cancer in African American, 
compared to Caucasian, patients [7, 9, 20, 21]. These 
disparities reflect advanced stage at diagnosis, socio-
economic factors, and differences in disease man-
agement [6-9, 22-24]. However, beyond these param-
eters which influence overall disease outcomes, there 
are racial differences in stage-specific outcomes [6, 8, 
9, 25]. Unexpectedly, the biggest differences in out-
comes occur in disease at the earliest stages, with 
more than 40% excess mortality in African Americans 
with lymph node-negative colorectal cancer, com-
pared to Caucasians. These stage-specific differences 
do not reflect socioeconomic factors, healthcare ac-
cess, or customs [6, 8, 9, 25]. However, they could re-
flect greater occult metastases in regional lymph 
nodes [8, 9]. Molecular approaches, which can quan-
tify small nests of metastatic tumor cells, represent a 
technological opportunity to reduce racial disparities 
in colorectal cancer mortality [5, 11, 26-29]. 
Enabling technologies 
Histopathology underestimates regional lymph 
node metastases, reflecting limitations in tissue vol-
umes sampled and detection sensitivity (one tumor 
cell in 200 normal cells) [16]. The significance of these 
restrictions can be understood by considering clini-
cally-impactful categories of lymph node metastases, 
including those that are greater than 0.2 cm (signifi-
cant), micrometastases between 0.02 to 0.2 cm (inde-
terminate significance), and isolated tumor cells less 
than 0.02 cm (low significance) [1, 3]. In that context, 
evolving molecular approaches provide highly sensi-
tive techniques that detect and characterize small 
quantities of cancer cells at metastatic foci. Enabling 
technologies, including RT-qPCR, may offer the most 
sensitive and specific detection of metastases [4, 5]. 
Molecular approaches to staging offer advantages that 
overcome limitations in histopathology, with the 
ability to sample the entire specimen, overcoming 
limitations in tissue sampling, and detect one tumor 
cell in ~107 normal cells, overcoming limitations in 
sensitivity [4, 5]. Early experience with RT-PCR has 
been heterogeneous, because of inadequate sample 
size, clinical follow-up, and techniques. However, 
meta-analyses reveal the prognostic utility of occult 
metastases in histopathology-negative regional lymph 
nodes detected by RT-PCR in colorectal cancer pa-
tients [4, 5]. 
GUCY2C is a molecular marker in colo-
rectal cancer 
GUCY2C, selectively expressed by intestinal ep-
ithelial cells, is the receptor for the paracrine factors 
guanylin and uroguanylin, whose binding to the ex-
tracellular domain activates the catalytic domain in 
the cytoplasm, producing cGMP accumulation [11, 30, 
31]. GUCY2C regulates epithelial homeostasis, coor-
dinating the cell cycle, chromosomal stability, metab-
olism, and microenvironmental interactions organiz-
ing the crypt-surface axis along the colon and rectum 
[32]. Guanylin and uroguanylin are gene products 
universally lost early in in colorectal tumorigensis in 
animals and humans. GUCY2C silencing in mice in-
creases tumorigenesis, reflecting dysregulation of cell 
proliferation and accumulation of DNA damage. 
Thus, GUCY2C is a tumor suppressor coordinating 
epithelial homeostasis whose silencing through hor-
mone loss contributes to tumorigenesis [32]. 
The unique expression pattern of GUCY2C, re-
stricted to intestinal epithelial cells normally, sug-
gested that this receptor might be a biomarker for 
colorectal cancer. Indeed, GUCY2C was expressed by 
>1,000 specimens of normal intestine, but not by 
>1,000 extra-gastrointestinal tissues [11, 30, 31]. Also, 
GUCY2C mRNA (n>900) and protein (n>200) were 
detected in almost all primary and metastatic human 
colorectal tumors, but not in extra-gastrointestinal 
tumors (>200). Moreover, GUCY2C mRNA and pro-
tein are over-expressed by nearly all colorectal tu-
mors. Taken together, these observations underscore 
the utility of GUCY2C as a marker for staging patients 
with colorectal cancer. 
Clinical utility of GUCY2C RT-qPCR for 
staging 
The utility of GUCY2C RT-PCR as a categorical 
variable (yes/no) for detecting occult tumor cells in 
regional lymph nodes that predict outcomes [27, 33] 
was defined in a prospective multicenter blinded 
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clinical trial. This trial was supported by an analyti-
cally validated sensitive, robust, and reproducible 
quantitative RT-PCR (RT-qPCR) method for GUCY2C 
[34, 35]. Further, it required unique statistical para-
digms for accurate quantification of GUCY2C con-
centrations that could stratify the prognostic risk of 
cohorts of patients providing different numbers of 
regional lymph nodes for analysis [11, 36]. In this trial, 
257 patients with lymph node-negative (stage I and II) 
colorectal cancer were prospectively enrolled at 9 
hospitals, providing 2,570 lymph nodes for analysis 
by histopathology and RT-qPCR. Patients were 
tracked for a median of 24 months and main outcomes 
were time to recurrence and disease-free survival [11]. 
Thirty-two (12.5%) patients had nodes that were neg-
ative for GUCY2C, and thirty remained free of disease 
(recurrence rate 6.3% [95% CI 0.8-20.8%]). Conversely, 
225 (87.5%) patients had regional lymph nodes that 
were positive for GUCY2C, and 47 (20.9% 
[15.8-26.8%]) developed recurrent disease (P=0.006). 
Indeed, GUCY2C in regional lymph nodes was the 
most powerful independent marker of prognosis, and 
patients who were GUYC2C-positive had earlier time 
to recurrence (adjusted hazard ratio 4.66 [1.11-19.57]; 
P=0.035) and lower disease-free survival (adjusted 
hazard ratio 3.27 [1.15-9.29]; P=0.026). Of significance, 
this is one of the first prospective multicenter blinded 
clinical trial offering level I evidence associating mo-
lecular lymph node metastases detected by RT-PCR 
with disease recurrence [11]. This trial reveals the 
utility of GUCY2C RT-qPCR to detect occult meta-
static tumor cells that define disease outcomes. This 
approach is quite robust with independent validation 
by other laboratories, operators and technology plat-
forms [37-39]. 
Although a high proportion of histologically 
node-negative patients harbor molecular metastases 
by GUCY2C RT-qPCR, most of these patients will 
never recur [1-3]. Understanding this apparent incon-
sistency depends on the realization that the presence 
of regional lymph node metastases does not insure 
disease recurrence but, rather, indicates risk of disease 
recurrence. This inability to identify clinically signifi-
cant from insignificant lymph node metastases rep-
resents one key gap in the management of patients 
with colorectal cancer. Indeed, this uncertainty can be 
appreciated by considering that only about 50% of 
stage III patients develop recurrent disease although 
all have metastases in regional lymph nodes detecta-
ble by histopathology [1-3]. 
Here, the uncertain clinical significance of occult 
metastases underscores the limitations of qualitative 
RT-PCR generally for categorical identification of oc-
cult metastases, which is the absence of quantitative 
information about metastatic burden [5]. The en-
hanced sensitivity of RT-PCR, with its maximized 
tissue sampling and ability to discriminate single 
cells, reveals metastases below the limit of prognostic 
risk [1, 5, 11, 28], restricting the specificity of this ap-
proach. There is an evolving approach that extends 
beyond the categorical detection of cancer cells, to 
quantify occult metastatic burden (how much) across 
the regional lymph node web to define disease risk 
and clinical outcomes. This algorithm originates in, 
and extends, established histopathological concepts. 
First, a quantitative relationship exists between 
prognostic risk and the number of nodes containing 
metastatic cancer cells by histopathology. For exam-
ple, stage III patients with more than 4 involved re-
gional lymph nodes exhibit a recurrence rate which is 
greater than patients with fewer than 3 involved 
lymph nodes [1-3]. Moreover, a quantitative rela-
tionship exists between the volume of metastatic tu-
mor cells in each lymph node and prognostic risk. In 
that context, metastases greater than 0.2 cm are asso-
ciated with increased cancer recurrence while the re-
lationship between individual tumor cells or nests less 
than 0.02 cm and risk is unclear [1-3]. The develop-
ment of quantitative RT-PCR (RT-qPCR) offers a re-
markable opportunity to quantify occult metastases to 
define prognostic risk and predict the benefit of ad-
juvant chemotherapy. Indeed, quantification of 
GUYC2C expression offers a molecular homologue of 
morphological analyses of metastatic volumes in re-
gional lymph nodes. Here, quantification by RT-qPCR 
enhances 2-dimensional morphology by estimating 
the amount of metastases in large volumes of lymph 
node materials, rather than thin sections, and across 
all lymph nodes to estimate occult metastatic burden 
throughout the regional lymph node web. 
Thus, we designed analytic approaches to define 
the association of occult metastatic burden, quantified 
by GUCY2C RT-qPCR, with outcomes in colorectal 
cancer patients to examine the quantitative relation-
ship between occult nodal metastases and prognostic 
risk [11, 13]. In this paradigm, relationships between 
clinical outcomes, including time to recurrence and 
disease-free survival, and occult metastatic burden, 
were estimated by recursive partitioning [13]. Here, 
176 (60%) stage I-II colon cancer patients exhibited 
low tumor burden (MolLow), and all but 4 remained 
free of disease (recurrence rate 2.3% [95%CI 
0.1-4.5%]). Further, 90 (31%) colon cancer patients 
exhibited intermediate tumor burden (MolInt) and 30 
(33.3% [23.7%-44.1%]) developed disease recurrence. 
Moreover, 25 (9%) colon cancer patients had high 
tumor burden (MolHigh), and 17 (68.0% 
[46.5%-85.1%]) developed recurrent disease (P<0.001). 
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Occult tumor burden was an independent marker of 
prognosis and patients with MolInt and MolHigh 
disease exhibited a graded risk of earlier time to re-
currence (MolInt, adjusted hazard ratio 25.52 
[11.08-143.18]; P<0.001; MolHigh, 65.38 [39.01-676.94]; 
P<0.001) and lower disease-free survival (MolInt, 9.77 
[6.26-87.26]; p<0.001; MolHigh, 22.97 [21.59-316.16]; 
P<0.001). This paradigm offers a remarkable en-
hancement to the use of GUCY2C as a categorical 
marker, where 88% of colorectal cancer patients were 
GUCY2C-positive with a recurrence risk of 20% [11]. 
They underscore the clinical opportunity offered by 
occult metastatic burden analysis to assign prognostic 
risk to patients with lymph node-negative colorectal 
cancer. In that context, identifying patients with a 
mortality risk equal to patients with disseminated 
metastases underscores the prognostic value of occult 
metastatic burden analysis. Additionally, patients 
with the greatest occult metastatic burden might ben-
efit most from receiving adjuvant chemotherapy. 
Racial disparities reflect differences in 
occult metastatic burden 
Prospective analysis of GUCY2C to detect occult 
metastases in regional lymph nodes [11, 13] provided 
an opportunity to define the contribution of occult 
metastatic burden to racial disparities in outcomes in 
colon cancer [12]. Indeed, there was 4-fold greater 
levels of occult metastases in individual nodes in 23 
African American, compared to 259 Caucasian, pa-
tients with colon cancer (p<0.001; 95% CI=3.3, 6.7). 
Occult metastatic burden across the regional lymph 
node web stratified the whole population into cate-
gories with low (60%; recurrence rate (RR)=2.3% [95% 
CI 0.1-4.5%]), intermediate (31%; RR=33.3% 
[23.7%-44.1%]), and high (9%; RR=68.0% 
[46.5%-85.1%], P<0.001) risk. However, race (P=0.02), 
T stage (p=0.02), and number of lymph nodes col-
lected for histology (P=0.003) were independent 
prognostic markers of risk. African American pa-
tients, compared to Caucasian patients, were most 
likely to have levels of occult metastatic burden pro-
ducing the greatest risk (adjusted odds ratio=5.08 
[1.55, 16.65]; P=0.007). These observations underscore 
occult metastatic burden as one determinant contrib-
uting to racial disparities in stage-specific outcomes in 
colorectal cancer. As a correlate, they suggest that 
occult metastatic burden may represent a detect-treat 
algorithm to reduce racial disparities in mortality in 
colorectal cancer. 
Number of lymph nodes optimizes the 
accuracy of occult metastatic analysis 
Not surprisingly, the accuracy of estimating oc-
cult metastatic burden is dependent on the number of 
regional lymph nodes analyzed by RT-qPCR [14]. 
Indeed, patients providing fewer than 5 regional 
lymph nodes exhibited occult metastatic burdens that 
identified more than 95% of stage I and II patients as 
low and intermediate risk, with few patients in the 
highest risk category. Conversely, analysis of more 
than 12 regional lymph nodes optimally resolved the 
lowest risk cohort, representing 68% of stage I and II 
patients. Further, analysis of more than 23 regional 
lymph nodes entirely eliminated the intermediate risk 
cohort, maximizing the identification of patients with 
the greatest recurrence risk, representing approxi-
mately 28% of stage I and II patients. Thus, the prog-
nostic utility of occult metastatic burden is related to 
the number of regional lymph nodes analyzed by 
RT-qPCR. Indeed, these data suggest that the inter-
mediate risk category reflects inaccuracies in esti-
mating occult tumor burden due to insufficient nodal 
collections. Based on these data, analysis of more than 
12 nodes offers estimates of occult metastatic burden 
that maximally define clinical outcomes, resolving 
stage I and II cohorts into patients with (1) with a 
near-zero likelihood of recurrence (~70%) and (2) a 
maximum likelihood (>70%) of recurrence (30%) [14]. 
Indeed, it may be the case that this algorithm provides 
near-perfect prognostic risk stratification, since ~70% 
of node-negative patients are cured by surgery, while 
~30% develop disease recurrence [1-3]. 
Future perspectives 
Staging patients with colorectal cancer involves 
histopathological analyses of tumors and regional 
lymph nodes. However, this paradigm un-
der-estimates the presence of metastases, and about 
30% of node-negative patients progress to developing 
disease recurrence. Limitations in established histo-
pathology techniques, including tissue sampling and 
sensitivity, can be overcome using emerging molecu-
lar approaches. Indeed, identification of occult me-
tastases in regional lymph nodes is the most powerful 
independent indicator of prognostic risk in colorectal 
cancer patients. Prospective clinical assessment indi-
cates that analyses of lymph nodes using RT-qPCR 
estimates metastatic burden that identifies those stage 
I and II patients that will develop recurrent disease. 
Further, these approaches suggest that occult meta-
static burden is one contributor to racial disparities in 
outcomes in African American, compared to Cauca-
sian, patients with colorectal cancer. Moreover, these 
at-risk stage I and II patients, black and white, may 
remarkably benefit from adjuvant chemotherapy. 
Beyond lymph node analysis, genomic para-
digms are evolving to extract clinically-important 
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information from tumors to enhance staging algo-
rithms to improve outcomes. Mutations in oncogenes 
or tumor suppressors, transcriptomic analyses, pro-
teomic and metabolomic signatures, and epigenetic 
profiling in tumors can personalize evaluations of 
risk, identify patients who could benefit from treat-
ment, and predict which treatments will be clinically 
active [40-44]. However, the clinical value of molecu-
lar analyses of primary tumors is only relevant in the 
context of whether primary tumors have metasta-
sized. Indeed, tumors with molecular signature sug-
gesting a poor prognosis represent a risk only if they 
are not excised before metastasizing. In that context, 
molecular approaches profiling tumors might be of 
greatest utility when applied to patients with occult 
metastatic burden, rather than to those free of metas-
tases in regional lymph nodes. Here, molecular anal-
yses of lymph nodes provides an opportunity to pri-
oritize expensive tumor analyses to optimize 
cost-effective healthcare [11]. Future clinical studies 
will explore the utility of analytical algorithms where 
patients who are node-negative by histopathology are 
reflexed to molecular staging, to quantify occult met-
astatic burden, followed subsequently by molecular 
tumor profiling for patients at increased prognostic 
risk, to define treatments individualized to their tu-
mor biology [45]. 
As a last note, while the technology for RT-qPCR 
is evolving, it remains primarily the province of spe-
cialty laboratories, with only modest penetration into 
hospitals and medical centers. However, molecular 
diagnostics is growing business, in excess of $14 bil-
lion with projected growth of 10% annually [46, 47]. In 
that context, molecular diagnostics approved by the 
FDA expanded from 72 in 2006 to 134 in 2009 [48]. 
Further, molecular tests developed in specialty labor-
atories were in excess of 1,400 in 2009 [49]. These data 
suggest that molecular diagnostics will be increas-
ingly integrated into the clinical care of patients. 
While specialty laboratories provide the experience 
and validated analytic algorithms consistent with 
FDA guidelines and CMS reimbursement in the short 
term, these enabling platforms will support integra-
tion of molecular staging into disease management 
algorithms across the entire healthcare enterprise in 
the long term. 
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